Previous 10 | Next 10 |
iBio (NYSE:IBIO) acquired the manufacturing facility it previously operated under a lease, from two affiliates of Eastern Capital. The company also acquired the ~30% equity interest in iBio CDMO LLC, held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are...
- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67% - BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of ne...
BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , today urged...
3 Hot Penny Stocks That Made Big Strides in Early October Right now, there is a large amount of momentum with both penny stocks and blue chips. And although many days have started down in October, we have seen solid bullish movement during the past week. If we look back at September, we...
Companies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. Investigational treatments are being developed at a rapid pace by numerous companies of all sizes. This includes biotech companies such as iBio (NYS...
iBio, Inc. (IBIO) Q4 Fiscal 2021 Earnings Conference Call September 27, 2021, 8:30 AM ET Company Participants Thomas Isett – Chairman & Chief Executive Officer Stephen Kilmer – Investor Relations Randy J Maddux – Chief Operating Officer Martin Brenner – Chief S...
Stock Market Futures Trading Sideways To Start The Week U.S. stock futures are looking for direction on Monday morning as investors tread cautiously in the last week of September. The general stock market sentiment seems to be improving. This came as investors digest the Fed...
Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming ® and Glycaneering TM Platforms to Accelerate Drug Devel...
9 Biotech Penny Stocks For Your October Watchlist Biotech penny stocks have remained some of the hottest small caps to buy over the past year and a half, and there are several good reasons for that. For one, the pandemic has highlighted both the importance of biotech and the potential t...
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , today anno...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...